Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case-control study

Cancer

Volumn 118, Issue 21, 2012, Pages 5384-5394

  Bracci, Paige M ^a   Zhou, Mi ^a   Young, Scott ^a   Wiemels, Joseph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antigens; autoantibodies; biomarkers; case control; pancreatic cancer

Indexed keywords

CANCER ANTIBODY; CARBOXY TERMINAL DOMAIN RNA POLYMERASE II POLYPEPTIDE A SMALL PHOSPHATASE 1 ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE 9 ANTIBODY; NUCLEAR RECEPTOR NR2E3 ANTIBODY; TOBACCO SMOKE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BODY MASS; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HOST RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SMOKING; SURVIVAL TIME; TUMOR IMMUNITY; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AUTOANTIBODIES; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; SAN FRANCISCO; TUMOR MARKERS, BIOLOGICAL;

EID: 84867870212     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27538     Document Type: Article

References (46)

1. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/ 1975-2007/. Based on November 2009 SEER data submission, posted to the SEER Web site, 2010.
2. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2011; 467: 1114-1117.
3. Eppel A, Cotterchio M, Gallinger S,. Allergies are associated with reduced pancreas cancer risk: A population-based case-control study in Ontario, Canada. Int J Cancer. 2007; 121: 2241-2245.
4. Holly EA, Eberle CA, Bracci PM,. Prior history of allergies and pancreatic cancer in the San Francisco Bay area. Am J Epidemiol. 2003; 158: 432-441.
5. Maisonneuve P, Lowenfels AB, Bueno-de-Mesquita HB, et al. Past medical history and pancreatic cancer risk: Results from a multicenter case-control study. Ann Epidemiol. 2010; 20: 92-98.
6. Olson SH, Orlow I, Simon J, et al. Allergies, variants in IL-4 and IL-4R alpha genes, and risk of pancreatic cancer. Cancer Detect Prev. 2007; 31: 345-351.
7. Wandall HH, Blixt O, Tarp MA, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010; 70: 1306-1313.
8. Gnjatic S, Ritter E, Büchler MW, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A. 2010; 107: 5088-5093.
9. Kim S, Cho H, Nam EJ, et al. Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer. Genes Chromosomes Cancer. 2010; 49: 585-595.
10. Piura E, Piura B,. Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. J Oncol. 2011; 2011: 982425.
11. Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol. 2011; 22: 383-389.
12. Zhang JY, Tan EM,. Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn. 2010; 10: 321-328.
13. Pedersen JW, Blixt O, Bennett EP, et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer. 2011; 128: 1860-1871.
14. Chan CC, Fan CW, Kuo YB, et al. Multiple serological biomarkers for colorectal cancer detection. Int J Cancer. 2010; 126: 1683-1690.
15. Babel I, Barderas R, Díaz-Uriarte R, et al. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics. 2009; 8: 2382-2395.
16. Anderson KS, LaBaer J,. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 2005; 4: 1123-1133.
17. Tan HT, Low J, Lim SG, et al. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009; 276: 6880-6904.
18. Casiano CA, Mediavilla-Varela M, Tan EM,. Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics. 2006; 5: 1745-1759.
19. Albertus DL, Seder CW, Chen G, et al. AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma. J Thorac Oncol. 2008; 3: 1236-1244.
20. Anderson KS, Wong J, Vitonis A, et al. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19: 859-868.
21. Bachelot T, Ratel D, Menetrier-Caux C, Wion D, Blay JY, Berger F,. Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer. 2006; 94: 1066-1070.
22. Budiu RA, Mantia-Smaldone G, Elishaev E, et al. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother. 2011; 60: 975-984.
23. Wadle A, Kubuschok B, Imig J, et al. Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer. 2006; 119: 117-125.
24. Duell EJ, Holly EA, Bracci PM, et al. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst. 2002; 94: 297-306.
25. Gong Z, Holly EA, Bracci PM,. Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999. Am J Epidemiol. 2011; 174: 1373-1381.
26. Hamanaka Y, Suehiro Y, Fukui M, et al. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer. 2003; 103: 97-100.
27. Heller A, Zörnig I, Müller T, et al. Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer. Cancer Immunol Immunother. 2010; 59: 1389-1400.
28. Hong SH, Misek DE, Wang H, et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res. 2004; 64: 5504-5510.
29. Li C, Kim HY, Vuong H, et al. The identification of auto-antibodies in pancreatic cancer patient sera using a naturally fractionated Panc-1 cell line. Cancer Biomark. 2010; 7: 25-37.
30. Li C, Simeone DM, Brenner DE, et al. Pancreatic cancer serum detection using a lectin/glyco-antibody array method. J Proteome Res. 2009; 8: 483-492.
31. Nakatsura T, Senju S, Ito M, et al. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol. 2002; 32: 826-836.
32. Nakatsura T, Senju S, Yamada K, et al. Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem Biophys Res Commun. 2001; 281: 936-944.
33. Okada T, Akada M, Fujita T, et al. A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers. Clin Cancer Res. 2006; 12: 191-197.
34. Patwa TH, Wang Y, Simeone DM, et al. Enhanced detection of autoantibodies on protein microarrays using a modified protein digestion technique. J Proteome Res. 2008; 7: 2553-2561.
35. Tomaino B, Cappello P, Capello M, et al. Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res. 2007; 6: 4025-4031.
36. Tomaino B, Cappello P, Capello M, et al. Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer. J Proteome Res. 2010; 10: 105-112.
37. Schmitz-Winnenthal FH, Galindo-Escobedo LV, Rimoldi D, et al. Potential target antigens for immunotherapy in human pancreatic cancer. Cancer Lett. 2007; 252: 290-298.
38. Kobold S, Lutkens T, Cao Y, et al. Autoantibodies against tumor-related antigens: incidence and biologic significance. Hum Immunol. 2010; 71: 643-651.
39. Hudson ME, Pozdnyakova I, Haines K, et al. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A. 2007; 104: 17494-17499.
40. Wang Y, Han KJ, Pang XW, et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol. 2002; 169: 1102-1109.
41. Ludwig N, Keller A, Heisel S, et al. Novel immunogenic antigens increase classification accuracy in meningioma to 93.84%. Int J Cancer. 2011; 128: 1493-1501.
42. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005; 353: 1224-1235.
43. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N,. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother. 2009; 58: 1535-1544.
44. Nolen B, Winans M, Marrangoni A, et al. Aberrant tumor-associated antigen autoantibody profiles in healthy controls detected by multiplex bead-based immunoassay. J Immunol Methods. 2009; 344: 116-120.
45. Angelopoulou K, Diamandis EP, Sutherland DJ, et al. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer. 1994; 58: 480-487.
46. Korangy F, Ormandy LA, Bleck JS, et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res. 2004; 10: 4332-4341.